• English
    X

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Middle Eastern Respiratory Syndrome Corona Virus (MERS-CoV) Testing at the Maryland Department of Health (MDH) Laboratory (2018)

    General Background

    Middle East Respiratory Syndrome (MERS) is an illness caused by a coronavirus known as Middle East Respiratory Syndrome Coronavirus (MERS-CoV) that first emerged in 2012 and has been linked to travel, or residence in, countries in and near the Arabian Peninsula. However, travel associated cases and outbreaks have occurred globally. Retrospective studies that demonstrated that MERS-CoV has spread from ill people to others through close contact, such as caring for or living with an infected person. Most MERS patients developed severe acute respiratory illness with symptoms of fever, cough, and shortness of breath. About 3 to 4 out of every 10 patients reported with MERS have died. MERS can affect anyone. MERS patients have ranged in age from younger than 1 to 99 years old.  For more information see the CDC website at:  https://www.cdc.gov/coronavirus/mers/hcp.html.
     
    What testing can the MDH Laboratories Perform
     
    The Maryland Department of Health (MDH) Laboratory has the capability to perform Middle Eastern Respiratory Syndrome Corona Virus (MERS-CoV) testing using a CDC developed real-time PCR assay under an FDA Emergency Use Authorization (EUA).  The MDH Laboratory can  also run parallel tests  for a variety of other more common respiratory pathogens such as influenza A, human metapneumovirus  and rhinoviruses that can present similar symptoms in patients who are suspected for MERS-CoV infections.
     

    Fact Sheets:

                 Fact Sheet for Health Care Professionals: Understanding Results from the CDC Novel Coronavirus 2012 Real-time RT-PCR Assay 

                 Fact Sheet for Patients: Understanding Results from the CDC Novel Coronavirus 2012 Real-time RT-PCR Assay 

                 Fact Sheet for Contacts: Understanding Results from the CDC Novel Coronavirus 2012 Real-time RT-PCR Assay

     
    When can the MDH Laboratories Conduct MERS-CoV Testing
     
    MERS-CoV testing can only be conducted with prior authorization from MDH physician–epidemiologists and is restricted to patients who meet the current CDC case definition (CDC link;
    https://www.cdc.gov/coronavirus/mers/case-def.html).
     
    Do not collect and submit specimens for MERS-CoV testing until an infectious disease consultation with the MDH physician-epidemiologist has been conducted and approval has been obtained to provide testing for the case.
     
    What steps to take if you suspect a MERS-CoV Infection
     
    To request MERS-CoV testing for a suspect case of MERS-CoV, contact the MDH Infectious Disease Bureau at 410-767-6700 during business hours, and after hours call the MDH Emergency Call Center at 410-795-7365 to arrange the initial infectious disease consultation.
     
    After the consultation, if MERS-CoV testing is indicated and authorized, the MDH Laboratory will contact you or your institution’s laboratory to make any additional logistical arrangements needed for expedited testing.
     
    Acceptable Specimens
     
    The MDH Laboratories requires that a lower respiratory, upper respiratory, and serum be collected on all suspect patients for MERS-CoV testing. Acceptable specimen types include the following:
    • Respiratory Specimens
      • Upper respiratory specimens-including nasopharyngeal* and/or oropharyngeal Swabs collected in Viral Transport Media, nasopharyngeal wash/aspirate, and nasal aspirate (*Please note that the Nasopharyngeal swab will be used to run the Biofire Respiratory Disease Panel)
      • Lower respiratory tract specimens-including Bronchoalveolar lavage, tracheal aspirate, sputum, and pleural fluid
    • Serum
    • Stool

     

    Specimen Collection Kit Instructions
     
    For periods of ≤72 hours, specimens should be held at 2-8 rather than frozen.  For delays exceeding 72 hours, freeze specimens at -70​ as soon as possible after collection unless otherwise noted.  Please be sure to label each specimen with patient name, specimen type, and date and time of collection. Specimen collection kits (Viral Culture Kit) can be ordered by the local health department by calling 443-681-3777 and submitting via email or fax the Outfit Supply Requisition form. (See link below)​

     
    Specimen Collection & Storage

     
    Completing the Test Request Form
     
    The MDH Laboratories Administration Form # 4676 Infectious Agents: Culture / Detection must be completed and submitted with each of the required specimens (1) nasopharyngeal swab, (2) serum, and (3) one of the following lower respiratory specimens (sputum, bronchoalveolar lavage, tracheal aspirate, or pleural fluid). Click on the links below for an example of the completed form #4676 and the electronic fillable form.
     
     
     
    Packaging and Shipping
     
    Specimens must be packaged in a triple packaging system to ensure that under normal conditions of transport they cannot break, be punctured or leak their contents (Refer to page 10 in the Lab Services Guide for Basic Triple Packaging Guidance).
     
     
    Contact Information: 
     
    To request MERS-CoV testing for a suspect case of MERS-CoV, contact the MDH Infectious Disease Bureau at 410-767-6700 during business hours, and after hours call the MDH Emergency Call Center at 410-795-7365 to arrange the initial infectious disease consultation.
     
    For questions or concerns, please contact the Division of Molecular Biology Laboratory at 443-681-3924 or 443-681-3800 during normal business hours from 8:00AM-4:30PM.